Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-495,162
Closed -$115M 9
2025
Q3
$115M Buy
+495,162
New +$101M 13.44% 2
2025
Q2
Sell
-542,984
Closed -$114M 20
2025
Q1
$114M Hold
542,984
16.69% 1
2024
Q4
$96.5M Hold
542,984
13.77% 2
2024
Q3
$107M Hold
542,984
14.83% 1
2024
Q2
$93.1M Hold
542,984
12.37% 2
2024
Q1
$98.9M Hold
542,984
10.55% 1
2023
Q4
$84.1M Buy
542,984
+23,181
+4% +$3.38M 9.42% 3
2023
Q3
$77.5M Buy
519,803
+1,000
+0.2% +$147K 9.57% 3
2023
Q2
$69.9M Buy
518,803
+7,688
+2% +$1.13M 8.33% 3
2023
Q1
$81.5M Hold
511,115
9.65% 2
2022
Q4
$82.6M Hold
511,115
10.45% 2
2022
Q3
$68.6M Hold
511,115
9.78% 2
2022
Q2
$78.3M Hold
511,115
10.36% 2
2022
Q1
$82.9M Sell
511,115
-15,122
-3% -$2.2M 9.51% 3
2021
Q4
$71.3M Buy
526,237
+7,013
+1% +$828K 8.8% 3
2021
Q3
$56M Buy
519,224
+2,750
+0.5% +$314K 7.72% 3
2021
Q2
$58.2M Buy
516,474
+6,100
+1% +$687K 8.35% 3
2021
Q1
$55.2M Buy
510,374
+44,263
+9% +$4.73M 8.79% 2
2020
Q4
$49.9M Buy
466,111
+1,150
+0.2% +$111K 9.21% 2
2020
Q3
$40.7M Hold
464,961
9.24% 3
2020
Q2
$45.6M Hold
464,961
11.5% 2
2020
Q1
$35.4M Hold
464,961
11.84% 2
2019
Q4
$41.2M Buy
+464,961
New +$38.6M 13.42% 2

Other funds holding ABBV

Criteria Caixa's ABBV Position: Q4 2025 in Review

Criteria Caixa sold out of AbbVie (ABBV) in Q4 2025, closing a stake of 495,162 shares — an estimated $115M sold.

Criteria Caixa first reported a position in ABBV in Q4 2019 and held it in 23 quarters. The position peaked at $115M in Q3 2025. 4,147 funds tracked by Wall St. Rank hold ABBV as of Q4 2025.

  • Criteria Caixa reported no remaining AbbVie position as of Q4 2025 after selling out during the quarter.
  • Criteria Caixa sold 495,162 AbbVie shares in Q4 2025, an estimated $115M.
  • Criteria Caixa first reported a position in AbbVie in Q4 2019 and held it in 23 quarters.
  • Criteria Caixa's AbbVie position peaked at $115M in Q3 2025.
  • 4,147 funds tracked by Wall St. Rank held AbbVie as of Q4 2025.

Based on Criteria Caixa's 13F filing for Q4 2025, filed 17 Feb 2026.